Last reviewed · How we verify
CEA CAR-T cells
At a glance
| Generic name | CEA CAR-T cells |
|---|---|
| Sponsor | Chongqing Precision Biotech Co., Ltd |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors (PHASE1)
- A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors (PHASE1)
- CEA CAR-T Therapy After Cytoreduction in Colorectal Cancer Patients With Peritoneal Metastases (PHASE1)
- CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors (PHASE1)
- Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Positive Advanced Lung Cancer (PHASE1)
- Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung Cancer (PHASE1)
- A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression (PHASE1, PHASE2)
- A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |